Ginkgo Bioworks Holdings, Inc. (DNA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-25) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | 8-K (2024-05-09) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-29) · 99.1 | 8-K (2024-01-10) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-08) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Changes In Shareholders' Equity | — |
|
| Consolidated Statements of Operations and Comprehensive Loss (P) | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Acquisitions | — |
|
| Acquisitions and Divestitures | — |
|
| Basis of Presentation and Summary of Significant Accounting Policies | — |
|
| Business Combination | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Discontinued Operations and Assets Held For Sale | — |
|
| Employee Benefit Plan | — |
|
| Fair Value Measurements | ||
| Goodwill and Intangible Assets, Net | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Investments and Equity Method Investments | ||
| Investments, Debt and Equity Securities | — |
|
| Leases | — |
|
| Marketable Securities | — |
|
| Net Loss Per Share | ||
| Organization and Basis of Presentation | — |
|
| Pay Vs Performance Disclosure | ||
| Related Parties | ||
| Related Party Disclosures | — |
|
| Restructuring | ||
| Revenue Recognition | ||
| Segment Information | ||
| Significant Collaboration Transactions | ||
| Significant Collaboration Transactions With Related Parties | — |
|
| Stock-based Compensation | ||
| Stockholders' Equity | — |
|
| Subsequent Events | ||
| Summary of Significant Accounting Policies | — |
|
| Supplemental Financial Information | ||
| Supplemental Information | — |
|
| Variable Interest Entities | ||
| Warrant Liabilities | — |
|